A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting
NCT05792228 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92
Last updated 2023-11-14
Summary
The goal of this clinical trial is to investigate the effect of a nurse-led standardized intervention on chemotherapy induced nausea and vomiting (CINV) in patients with head and neck squamous cell carcinoma. The main questions it aims to answer are: (1) what's the best practice to enhance the management of CINV; (2) how's the effect of the nurse-led standardized intervention on CINV in the patients treated with cisplatin-based chemotherapy. Participants in the intervention group will receive evidence-based, nurse-led standardized management of CINV, including nurse-led risk assessment, education on prevention and control of CINV, antiemetics following guidelines, dietary strategies, relaxation therapy, and follow up. Participants in the control group will receive routine care of CINV. The incidence and occurrence degree of CINV and its influence on patients' quality of life will be compared between the two groups.
Conditions
- Squamous Cell Carcinoma of Head and Neck
- Chemotherapy Induced Nausea and Vomiting
Interventions
- OTHER
-
nurse-led standardized intervention
Once the patient in the intervention group decided to undergo cisplatin-based chemotherapy, the nurses would assess the risk factors associated with chemotherapy-induced nausea and vomiting (CINV) and reported to the physicians. During the chemotherapy, nurses would provide education on prevention and control of CINV using web-based approaches. All patients received standard antiemetic regimen, which included Aprepitant, 5-Hydroxytryptamine3-receptor antagonists, and Dexamethasone. If the physician's prescription was not accordance with the standard antiemetic regimen, nurse would remind the physician to adjust the prescription. Patients were recommended to eat small and frequent meals slowly. Overly spicy, fatty, and sweet foods should be avoided. Music relaxation therapy was performed for 60 min each time, once a day, and 3 times in the whole chemotherapy cycle. Follow-up was delivered until the 5th day after chemotherapy.
Sponsors & Collaborators
-
Tianjin Medical University Cancer Institute and Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-04-02
- Primary Completion
- 2023-10-02
- Completion
- 2023-10-12
Countries
- China
Study Locations
More Related Trials
-
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
NCT06240689 ·Status: RECRUITING ·Phase: PHASE2
-
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
NCT04146402 ·Status: UNKNOWN ·Phase: PHASE3
-
Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer
NCT02879214 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical Trial
NCT04929067 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
NCT06100497 ·Status: RECRUITING ·Phase: PHASE2
-
Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma
NCT04678791 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT04982237 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC
NCT05351762 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical Cancer
NCT03175848 ·Status: UNKNOWN ·Phase: NA
-
Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial
NCT05338905 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
NCT05799469 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
NCT06692166 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
NCT05235516 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
NCT06492460 ·Status: RECRUITING ·Phase: PHASE3
-
A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
NCT06894459 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma
NCT06575322 ·Status: RECRUITING
-
The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer
NCT04409860 ·Status: RECRUITING ·Phase: NA
-
Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
NCT04319471 ·Status: UNKNOWN ·Phase: PHASE2
-
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
NCT02567422 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
NCT05173272 ·Status: RECRUITING ·Phase: PHASE3
-
Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer
NCT03029013 ·Status: UNKNOWN ·Phase: NA
-
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
NCT06289062 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer
NCT05189028 ·Status: RECRUITING ·Phase: PHASE3
-
Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer
NCT00002507 ·Status: COMPLETED ·Phase: PHASE3